Search Results - "McKay, Colin J."

Rab25 and CLIC3 Collaborate to Promote Integrin Recycling from Late Endosomes/Lysosomes and Drive Cancer Progression by Dozynkiewicz, Marta A., Jamieson, Nigel B., MacPherson, Iain, Grindlay, Joan, van den Berghe, Peter V.E., von Thun, Anne, Morton, Jennifer P., Gourley, Charlie, Timpson, Paul, Nixon, Colin, McKay, Colin J., Carter, Ross, Strachan, David, Anderson, Kurt, Sansom, Owen J., Caswell, Patrick T., Norman, Jim C.

“…Here we show that Rab25 permits the sorting of ligand-occupied, active-conformation α5β1 integrin to late endosomes/lysosomes. Photoactivation and biochemical…”
Get full text

A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma by Bradley, Alison, Van der Meer, Robert, McKay, Colin J

“…The narrative surrounding the management of potentially resectable pancreatic cancer is complex. Surgical resection is the only potentially curative treatment…”
Get full text

Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis by JAMIESON, Nigel B, CARTER, C. Ross, MCKAY, Colin J, OIEN, Karin A

“…The management of pancreatic ductal adenocarcinoma (PDAC) continues to present a great challenge particularly with regard to prediction of outcome following…”
Get full text

SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients by McGlynn, Liane M, McCluney, Simon, Jamieson, Nigel B, Thomson, Jackie, MacDonald, Alasdair I, Oien, Karin, Dickson, Euan J, Carter, C Ross, McKay, Colin J, Shiels, Paul G

“…The sirtuin gene family has been linked with tumourigenesis, in both a tumour promoter and suppressor capacity. Information regarding the function of sirtuins…”
Get full text

A systematic review of methodological quality of model development studies predicting prognostic outcome for resectable pancreatic cancer by Bradley, Alison, Van Der Meer, Robert, McKay, Colin J

“…ObjectivesTo assess the methodological quality of prognostic model development studies pertaining to post resection prognosis of pancreatic ductal…”
Get full text

The Prognostic Influence of Resection Margin Clearance Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma by Jamieson, Nigel B., Chan, Nigel I. J., Foulis, Alan K., Dickson, Euan J., McKay, Colin J., Carter, C. Ross

“…Introduction The poor overall survival associated with pancreatic ductal adenocarcinoma (PDAC) despite complete resection suggests that occult metastatic…”
Get full text

A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma by Jamieson, Nigel B., Denley, Simon M., Logue, Jennifer, MacKenzie, Douglas J., Foulis, Alan K., Dickson, Euan J., Imrie, Clem W., Carter, Ross, McKay, Colin J., McMillan, Donald C.

“…Background Outcome prediction after resection with curative intent for pancreatic ductal adenocarcinoma remains a challenge. There is increasing evidence that…”
Get full text

Serum amylase on the night of surgery predicts clinically significant pancreatic fistula after pancreaticoduodenectomy by Palani Velu, Lavanniya K, Chandrabalan, Vishnu V, Jabbar, Salman, McMillan, Donald C, McKay, Colin J, Carter, C. Ross, Jamieson, Nigel B, Dickson, Euan J

“…Abstract Objectives Drainage after pancreaticoduodenectomy (PD) remains controversial because the risk for uncontrolled postoperative pancreatic fistula (POPF)…”
Get full text

Chronic inflammation and pancreatic cancer by McKay, Colin J., MD, Glen, Paul, MBChB, McMillan, Donald C., PhD

“…There is a proven association between carcinoma of the pancreas and both the sporadic and hereditary forms of chronic pancreatitis. In chronic pancreatitis the…”
Get full text

Pre-operative cardiopulmonary exercise testing predicts adverse post-operative events and non-progression to adjuvant therapy after major pancreatic surgery by Chandrabalan, Vishnu V, McMillan, Donald C, Carter, Roger, Kinsella, John, McKay, Colin J, Carter, C. Ross, Dickson, Euan J

“…Abstract Background Surgery followed by chemotherapy is the primary modality of cure for patients with resectable pancreatic cancer but is associated with…”
Get full text

Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling by Dreyer, Stephan B, Jamieson, Nigel B, Evers, Lisa, Duthie, Fraser, Cooke, Susie, Marshall, John, Beraldi, Dario, Knight, Stephen, Upstill-Goddard, Rosanna, Dickson, Euan J, Carter, C Ross, McKay, Colin J, Biankin, Andrew V, Chang, David K

“…Next-generation sequencing is enabling molecularly guided therapy for many cancer types, yet failure rates remain relatively high in pancreatic cancer (PC)…”
Get full text

Peripancreatic Fat Invasion Is an Independent Predictor of Poor Outcome Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma by Jamieson, Nigel Balfour, Foulis, Alan K., Oien, Karin A., Dickson, Euan J., Imrie, Clem W., Carter, Ross, McKay, Colin J.

“…Background Following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma (PDAC), identification of peripancreatic fat tumor invasion promotes a tumor…”
Get full text

The Surveillance Strategy for Intraductal Pancreatic Mucinous Neoplasms: Criteria for Discontinuation by McGuigan, Mari-Claire, Hadjicosti, Rafaella, Cameron, Andrew J, Coats, Maria, Chang, David, Dickson, Euan J, Holroyd, David, McKay, Colin J, Jamieson, Nigel B

“…To review the surveillance of IPMN, the risk of pancreatic cancer and the cost of surveillance. The increasing IPMN prevalence and low pancreatic cancer…”
Get full text

MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma by JAMIESON, Nigel B, MORRAN, Douglas C, MORTON, Jennifer P, ALI, Asif, DICKSON, Euan J, ROSS CARTER, C, SANSOM, Owen J, EVANS, T. R. Jeffry, MCKAY, Colin J, OIEN, Karin A

“…MicroRNAs (miRNA) have potential as diagnostic and prognostic biomarkers and as therapeutic targets in cancer. We sought to establish the relationship between…”
Get full text

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial by Neoptolemos, John P, Stocken, Deborah D, Bassi, Claudio, Ghaneh, Paula, Cunningham, David, Goldstein, David, Padbury, Robert, Moore, Malcolm J, Gallinger, Steven, Mariette, Christophe, Wente, Moritz N, Izbicki, Jakob R, Friess, Helmut, Lerch, Markus M, Dervenis, Christos, Oláh, Attila, Butturini, Giovanni, Doi, Ryuichiro, Lind, Pehr A, Smith, David, Valle, Juan W, Palmer, Daniel H, Buckels, John A, Thompson, Joyce, McKay, Colin J, Rawcliffe, Charlotte L, Büchler, Markus W, European Study Group for Pancreatic Cancer, for the

“…CONTEXT Adjuvant fluorouracil has been shown to be of benefit for patients with resected pancreatic cancer. Gemcitabine is known to be the most effective agent…”
Get full text

RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial by Palani Velu, Lavanniya K, Steele, Colin W, Dickson, Euan J, Carter, C Ross, McKay, Colin J, Horgan, Paul G, McMillan, Donald C, Jamieson, Nigel B

Get full text

Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer by Dreyer, Stephan B., Pinese, Mark, Jamieson, Nigel B., Scarlett, Christopher J., Colvin, Emily K., Pajic, Marina, Johns, Amber L., Humphris, Jeremy L., Wu, Jianmin, Cowley, Mark J., Chou, Angela, Nagrial, Adnan M., Chantrill, Lorraine, Chin, Venessa T., Jones, Marc D., Moran-Jones, Kim, Carter, Christopher Ross, Dickson, Euan J., Samra, Jaswinder S., Merrett, Neil D., Gill, Anthony J., Kench, James G., Duthie, Fraser, Miller, David K., Cooke, Susanna, Aust, Daniela, Knösel, Thomas, Rümmele, Petra, Grützmann, Robert, Pilarsky, Christian, Nguyen, Nam Q., Musgrove, Elizabeth A., Bailey, Peter J., McKay, Colin J., Biankin, Andrew V., Chang, David K.

“…OBJECTIVE:We aimed to define preoperative clinical and molecular characteristics that would allow better patient selection for operative resection…”
Get full text

Positive Mobilization Margins Alone Do Not Influence Survival Following Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma by JAMIESON, Nigel B, FOULIS, Alan K, OIEN, Karin A, GOING, James J, GLEN, Paul, DICKSON, Euan J, IMRIE, Clem W, MCKAY, Colin J, CARTER, Ross

“…To determine the prognostic influence of residual tumor at or within 1 mm of the mobilization margins (R1Mobilization) compared with transection margins…”
Get full text

Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer by Dreyer, Stephan B, Pinese, Mark, Jamieson, Nigel B, Scarlett, Christopher J, Colvin, Emily K, Pajic, Marina, Johns, Amber L, Humphris, Jeremy L, Wu, Jianmin, Cowley, Mark J, Chou, Angela, Nagrial, Adnan M, Chantrill, Lorraine, Chin, Venessa T, Jones, Marc D, Moran-Jones, Kim, Carter, Christopher Ross, Dickson, Euan J, Samra, Jaswinder S, Merrett, Neil D, Gill, Anthony J, Kench, James G, Duthie, Fraser, Miller, David K, Cooke, Susanna, Aust, Daniela, Knösel, Thomas, Rümmele, Petra, Grützmann, Robert, Pilarsky, Christian, Nguyen, Nam Q, Musgrove, Elizabeth A, Bailey, Peter J, McKay, Colin J, Biankin, Andrew V, Chang, David K

“…We aimed to define preoperative clinical and molecular characteristics that would allow better patient selection for operative resection. Although we use…”
Get full text

The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer by Dreyer, Stephan B, Rae, Sarah, Bisset, Kirsty, Upstill-Goddard, Rosie, Gemenetzis, Georgios, Johns, Amber L, Dickson, Euan J, Mittal, Anubhav, Gill, Anthony J, Duthie, Fraser, Pea, Antonio, Lawlor, Rita T, Scarpa, Aldo, Salvia, Roberto, Pulvirenti, Alessandra, Zerbi, Alessandro, Marchesi, Federica, McKay, Colin J, Biankin, Andrew V, Samra, Jaswinder S, Chang, David K, Jamieson, Nigel B

“…The long-term outcomes following surgical resection for pancreatic ductal adenocarcinoma (PDAC) remains poor, with only 20% of patients surviving 5 years after…”
Get full text